Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest OncoGenex Pharmaceuticals Inc. Stories

2014-03-11 16:26:27

Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced fourth quarter and year end 2013 financial results. Clinical Developments and Anticipated Near-term Milestones -- Custirsen -- The SYNERGY Phase 3 trial is designed to...

2014-02-25 08:30:53

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 25, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and year-ended 2013 financial results will be released on Tuesday, March 11, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update. To...

2014-02-11 08:30:37

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer...

2014-02-06 08:27:24

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 6, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 8:50 a.m. ET at the Waldorf Astoria Hotel in New York City. A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at...

2013-11-19 08:27:15

SYNERGY Trial to Continue as Planned Following Completion of Interim Efficacy Analysis BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 19, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the SYNERGY trial is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC). The primary registration Phase 3 SYNERGY trial is designed to evaluate a survival benefit for custirsen in combination with first-line...

2013-11-07 16:30:43

Conference call to be held on Thursday, November 7 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently asked questions from investors during the quarterly conference call. Questions, including recent inquiries regarding the clinical development program and prostate cancer market landscape, were submitted via the...

2013-11-05 08:33:17

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona. A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at...

2013-10-30 08:30:27

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2013 financial results will be released on Thursday, November 7, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results and will address frequently asked questions from investors. "For this quarter's...

2013-08-27 08:26:37

Pancreatic Cancer Joins Bladder, Lung and Prostate Cancers as Tumor Types with Phase 2 Trials Open for Enrollment as Part of the ORCA(TM) Program BOTHELL, Wash. and VANCOUVER, Aug. 27, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Rainier(TM) clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen (OGX-427) in combination with ABRAXANE® (paclitaxel protein-bound particles for...

2013-08-08 16:26:58

Conference call to be held on Thursday, August 8 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 8, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and apatorsen (OGX-427), and announced second quarter 2013 financial results. Custirsen Program Update -- The primary registration Phase 3 SYNERGY trial, designed to evaluate a...